

Javier P Gisbert

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8181711/javier-p-gisbert-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417
papers

19,074
citations

72
h-index

125
g-index

526
ext. papers

23,761
ext. citations

3.5
avg, IF

7.04
L-index

#	Paper	IF	Citations
417	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.. <i>Frontiers in Medicine</i> , 2022 , 9, 823900	4.9	0
416	Assessment of first-line eradication treatment in Greece: data from the European Registry on management (Hp-EuReg).. <i>Annals of Gastroenterology</i> , 2022 , 35, 42-47	2.2	1
415	Evaluation of Natural Language Processing for the Identification of Crohn Disease-Related Variables in Spanish Electronic Health Records: A Validation Study for the PREMONITION-CD Project.. <i>JMIR Medical Informatics</i> , 2022 , 10, e30345	3.6	0
414	How to prepare a research proposal in the health sciences?. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 730-740	0.9	1
413	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 671-679	0.9	
412	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
411	Etolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	7
410	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, e837-e842	2.2	
409	Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 34,	2.2	1
408	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	2
407	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	19
406	How to prepare a research proposal in the health sciences. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 , 44, 730-730	0.1	
405	V Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología</i> , 2021 ,	0.9	3
404	Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study). <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 628-636	0.9	
403	Epidemiological and clinical characteristics, and response to treatment in 113 patients with microscopic colitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 , 44, 671-671	0.1	
402	Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 721-723	0.9	1
401	Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management. <i>Digestive Diseases</i> , 2021 , 39, 318-324	3.2	1

400	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	12
399	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
398	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1846-1851	1.5	3
397	Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. <i>Microorganisms</i> , 2021 , 9,	4.9	21
396	Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 806-811	2.4	0
395	Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). <i>American Journal of Gastroenterology</i> , 2021 , 116, 1220-1229	0.7	15
394	DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn's Disease patients: Results from the IBDomics study. <i>Journal of Crohns and Colitis</i> , 2021 , 15, S057-S058	1.5	
393	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
392	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , 2021 , 65, e2001034	5.9	2
391	Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1277-1288	6.1	1
390	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
389	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021 , 9, 766	5.3	6
388	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1180-1188.e4	6.9	6
387	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 35-42	1.5	13
386	European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <i>United European Gastroenterology Journal</i> , 2021 , 9, 38-46	5.3	2
385	European Registry on management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. <i>Gut</i> , 2021 , 70, 40-54	19.2	41
384	Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). <i>Journal of Clinical Gastroenterology</i> , 2021 , Publish Ahead of Print,	3	9
383	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	4

382	Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1184-1200	4.5	0
381	Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1041-1051	6.1	1
380	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , 2021 , 161, 495-507.e4	13.3	14
379	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021 , 29, 1573-1588.e7	23.4	9
378	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021 , 44, 599-599	0.1	
377	Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
376	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Getecu. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
375	Challenges of independent clinical research. <i>Gastroenterología Y Hepatología</i> , 2021 , 44, 599-610	0.9	1
374	Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 144, 112239	7.5	3
373	The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211018097	4.7	2
372	European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in Israel. <i>Israel Medical Association Journal</i> , 2021 , 23, 38-42	0.9	1
371	Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	1
370	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	1
369	Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi): a multidisciplinary perspective.. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-13	5.4	0
368	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-β results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1021-1029	6.1	2
367	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 606-616	4.5	19
366	Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones. <i>Molecules</i> , 2020 , 25,	4.8	3
365	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 117-125	0.9	1

364	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
363	A quick flow cytometry protocol to assess <i>Helicobacter pylori</i> viability. <i>Journal of Microbiological Methods</i> , 2020 , 177, 106043	2.8	2
362	P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S482-S483	1.5	15
361	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2080-2087	4	9
360	Errors in the care of inflammatory bowel disease patients: Errata Study. <i>Gastroenterology Y Hepatología (English Edition)</i> , 2020 , 43, 233-239	0.1	
359	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of <i>Helicobacter pylori</i> infection. <i>Gastroenterology Y Hepatología (English Edition)</i> , 2020 , 43, 117-125	0.1	
358	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 588-596	2.2	2
357	Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. <i>Drugs</i> , 2020 , 80, 1085-1100	12.1	12
356	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 870-879	6.1	4
355	<i>Helicobacter pylori</i> first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on <i>H. pylori</i> management (Hp-EuReg). <i>Helicobacter</i> , 2020 , 25, e12686	4.9	15
354	Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. <i>EMBO Molecular Medicine</i> , 2020 , 12, e10862	12	21
353	Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 155-168	0.9	7
352	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 649-658	0.9	1
351	P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S594-S597	1.5	3
350	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1037-1048	1.5	30
349	Systematic review: gastric microbiota in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 582-602	6.1	66
348	P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S359-S360	1.5	
347	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1290-1298	1.5	4

346	Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. <i>Helicobacter</i> , 2020 , 25, e12693	4.9	12
345	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1802-1811	0.7	5
344	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 79-86	0.9	
343	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 551-558	0.1	0
342	European Registry on Management: Effectiveness of First and Second-Line Treatment in Spain. <i>Antibiotics</i> , 2020 , 10,	4.9	2
341	Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring. <i>Nutrients</i> , 2020 , 13,	6.7	10
340	Rifabutin for the Treatment of Infection: A Review. <i>Pathogens</i> , 2020 , 10,	4.5	11
339	P128 Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real life experience. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S201-S201	1.5	
338	Survey of adherence to treatment in inflammatory bowel disease. ENADEII study. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 285-292	0.9	0
337	Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 688-693	0.9	0
336	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 4-22	1.5	320
335	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 155-168	1.5	122
334	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 97-105	0.9	
333	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 694-709	1.5	54
332	Review - Treatment of Helicobacter pylori infection 2020. <i>Helicobacter</i> , 2020 , 25 Suppl 1, e12743	4.9	8
331	P040 Proteomic characterisation of serum extracellular vesicles in patients with inflammatory bowel diseases: a novel approach for biomarker discovery. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S152-S153	1.5	5
330	P086 Identification of constitutive modifications in plasma cells and B lymphocytes in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S177-S178	1.5	
329	P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S416-S418	1.5	

328	Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for <i>Helicobacter pylori</i> infection: Spanish data of the European <i>Helicobacter pylori</i> Registry (Hp-EuReg). <i>Helicobacter</i> , 2020 , 25, e12722	4.9	5
327	The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 551-558	0.9	8
326	Empirical or susceptibility-guided treatment for infection? A comprehensive review. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820968736	4.7	13
325	Tips and guidelines for being a successful researcher. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 540-550	0.9	3
324	Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 79-86	0.1	
323	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1056-1066	5.3	10
322	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1062-1066	2.2	2
321	Errors in the care of inflammatory bowel disease patients: "Errata" Study. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 233-239	0.9	
320	Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease". <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e6	4.5	
319	The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 557-566	1.5	11
318	Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 89-98	6.9	32
317	Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 273-283	0.9	3
316	P138 Prediction model to safely cease anti-TNF therapy in Crohn's disease: individual patient data meta-analysis (IPD-MA). <i>Journal of Crohns and Colitis</i> , 2019 , 13, S158-S159	1.5	0
315	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2460-2463	3.8	9
314	Increased risk of thiopurine-related adverse events in elderly patients with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 780-788	6.1	20
313	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819867848	4.7	
312	Warnings on the safety of quinolones: Should <i>Helicobacter pylori</i> treatment prescriptions be modified?. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 461-463	0.1	
311	DOP44 Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S052-S053	1.5	

310	P526 Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S376-S376	1.5	
309	Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity. <i>Immunity</i> , 2019 , 50, 446-461.e9	32.3	87
308	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 996-1002	1.5	24
307	Randomised clinical trial: intravenous vs oral iron for the treatment of anaemia after acute gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 258-268	6.1	7
306	Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 278-288	6.1	32
305	A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent infection. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1051-1063	5.3	18
304	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819847034	4.7	9
303	Effectiveness and Safety of the Switch from Remicade [®] to CT-P13 in Patients with Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1380-1386	1.5	14
302	Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019 , 24, e12593	4.9	10
301	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1492-1500	1.5	24
300	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 403-412	0.9	12
299	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <i>Pharmacogenomics Journal</i> , 2019 , 19, 547-555	3.5	2
298	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S529-S531	1.5	
297	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 90-101	0.1	
296	Role of food proteins and bioactive peptides in inflammatory bowel disease. <i>Trends in Food Science and Technology</i> , 2019 , 88, 194-206	15.3	31
295	P223 Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S207-S208	1.5	
294	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S321-S322	1.5	1
293	Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIATE trial. <i>Digestive and Liver Disease</i> , 2019 , 51, 529-535	3.3	2

292	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019 , 37, 266-283	3.2	29
291	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , 2019 , 15, 63-68	0.9	0
290	Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2019 , 24, e12570	4.9	29
289	P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S410-S410	1.5	
288	Warnings on the safety of quinolones: Should <i>Helicobacter pylori</i> treatment prescriptions be modified?. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 461-463	0.9	2
287	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg). <i>Helicobacter</i> , 2019 , 24, e12630	4.9	22
286	Efficacy of tofacitinib treatment in ulcerative colitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 403-412	0.1	1
285	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 568-578	0.9	5
284	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019 , 11,	6.7	15
283	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S328-S329	1.5	
282	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. <i>EBioMedicine</i> , 2019 , 48, 648-655	8.8	30
281	Review: Treatment of <i>Helicobacter pylori</i> Infection 2019. <i>Helicobacter</i> , 2019 , 24 Suppl 1, e12640	4.9	22
280	P013 Novel immunomodulatory role of food bioactive peptide lunasin in the healthy human intestinal mucosa. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S092-S093	1.5	
279	Empirical <i>Helicobacter pylori</i> rescue therapy: an 18-year single-centre study of 1200 patients. <i>GastroHep</i> , 2019 , 1, 311-324	1	7
278	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2822-2823	6.9	
277	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819874202	4.7	0
276	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. <i>Inflammatory Intestinal Diseases</i> , 2019 , 4, 161-173	2.5	0
275	Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 242-250	6.1	12

274	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 127-137	1.5	23
273	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 846-854	4	15
272	Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 90-101	0.9	7
271	Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 419-428	6.1	18
270	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , 2019 , 52, 459-468	5.1	8
269	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 374-384	1.5	20
268	Long-Term Safety of In Utero Exposure to Anti-TNF Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 396-403	0.7	92
267	P156 Differential characteristics of patients with inflammatory bowel disease onset in paediatric age compared with patients diagnosed in adulthood: Results from the CAROUSEL study of GETECCU. <i>Journal of Crohns and Colitis</i> , 2018 , 12, S174-S176	1.5	
266	Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 272-280	0.1	
265	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 205-221	0.1	2
264	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 205-221	0.9	23
263	Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 272-280	0.9	7
262	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 605-614	6.1	38
261	Human Intestinal Dendritic Cells in Inflammatory Bowel Diseases. <i>Molecular Nutrition and Food Research</i> , 2018 , 62, e1700931	5.9	24
260	Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 532-537	1.5	5
259	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018 , 50, 353-359	3.3	19
258	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 118-127	0.9	13
257	Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 972-979	0.7	30

256	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut</i> , 2018 , 67, 237-243	19.2	84
255	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 63-76	0.9	3
254	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 17-31	1.5	83
253	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 514-529	0.9	23
252	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1270-1279	1.5	12
251	Acute severe ulcerative colitis: State of the art treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 32-33, 59-69	2.5	20
250	Human intestinal pro-inflammatory CD11cCCR2CX3CR1 macrophages, but not their tolerogenic CD11cCCR2CX3CR1 counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 1114-1126	9.2	56
249	Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , 2018 , 23, e12529	4.9	17
248	<i>Helicobacter Pylori</i> Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on <i>Helicobacter Pylori</i> Management. <i>Radiology and Oncology</i> , 2018 , 52, 1-6	3.8	5
247	European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg): Analysis of 2360 patients receiving first-line therapy in Russia. <i>Terapevticheskii Arkhiv</i> , 2018 , 90, 35-42	0.9	4
246	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 63-76	0.1	1
245	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 839-851	6.1	53
244	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 514-529	0.1	1
243	Treatment of <i>Helicobacter pylori</i> infection in 2018. <i>Helicobacter</i> , 2018 , 23 Suppl 1, e12519	4.9	31
242	Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14. <i>International Journal of Cancer</i> , 2018 , 143, 2777-2786	7.5	5
241	The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1649-1659	4.5	28
240	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 389-405	0.9	17
239	Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 389-405	0.1	1

238	Mentor-mentee relationship in medicine. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 48-57	0.9	6
237	Current treatment of Helicobacter pylori infection. <i>Medicina Clínica (English Edition)</i> , 2017 , 148, 20-22	0.3	
236	Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment. <i>Digestive and Liver Disease</i> , 2017 , 49, 973-977	3.3	14
235	Optimization strategies aimed to increase the efficacy of H.pylori eradication therapies. <i>Helicobacter</i> , 2017 , 22, e12392	4.9	40
234	Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1135-1143	0.7	15
233	Reply. <i>Gastroenterology</i> , 2017 , 152, 303-304	13.3	2
232	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017 , 77, 765-776	12.1	16
231	Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. <i>Gut</i> , 2017 , 66, 6-30	19.2	1488
230	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 481-490	4	31
229	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2017 , 112, 120-131	0.7	66
228	Non-responsive coeliac disease: Coeliac crisis vs. refractory coeliac disease with response to corticosteroids. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 529-530	0.9	1
227	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 651-657	0.9	8
226	Letter: the definition of budesonide dependence in microscopic colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 635	6.1	3
225	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 688-698	0.9	8
224	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 1086-1091	3.3	15
223	Ratio of Circulating Estrogen Receptors Beta and Alpha (ER β /ER α) Indicates Endoscopic Activity in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2744-2754	4	20
222	Treatment of Helicobacter pylori infection 2017. <i>Helicobacter</i> , 2017 , 22 Suppl 1, e12410	4.9	18
221	Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection. <i>International Journal of Clinical Practice</i> , 2017 , 71, e13004	2.9	7

220	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 472-483	0.9	18
219	Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1430-1439	1.5	72
218	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. <i>Gastroenterología Y Hepatología</i> , 2017 , 40, 658-662	0.9	8
217	Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1761-1764	0.7	11
216	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1394-1402	4.5	47
215	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. <i>Biomarkers</i> , 2017 , 22, 133-144	2.6	11
214	Ustekinumab to treat Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017 , 40, 688-698	0.1	
213	Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017 , 40, 651-657	0.1	
212	Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017 , 40, 658-662	0.1	
211	Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer. <i>PLoS ONE</i> , 2017 , 12, e0176043	3.7	13
210	Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis. <i>Journal of Pathology</i> , 2016 , 240, 425-436	9.4	30
209	Treatment of Helicobacter pylori infection 2016. <i>Helicobacter</i> , 2016 , 21 Suppl 1, 55-61	4.9	10
208	Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. <i>The Cochrane Library</i> , 2016 , CD009034	5.2	19
207	Towards effective empirical treatment for Helicobacter pylori eradication. <i>Lancet, The</i> , 2016 , 388, 2325-2326	4.1	2
206	Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 102	6.1	
205	Letter: oral low-dose methotrexate for collagenous colitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 98	6.1	
204	Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1662-9	4.5	113
203	Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2740-53	5.1	21

202	Maintenance therapy options for ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1339-42	4.2	13
201	Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 437-48	4.7	23
200	Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study). <i>United European Gastroenterology Journal</i> , 2016 , 4, 229-35	5.3	5
199	Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish Follow-up multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 953-8	4	62
198	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 261-8	0.7	30
197	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. <i>Digestive and Liver Disease</i> , 2016 , 48, 601-7	3.3	21
196	Effectiveness of anti-TNF drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF agent. <i>Digestive and Liver Disease</i> , 2016 , 48, 613-9	3.3	9
195	Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 657-62	1.5	17
194	Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 168-9	6.1	
193	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 632-47	0.7	99
192	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. <i>Digestive and Liver Disease</i> , 2016 , 48, 592-600	3.3	24
191	Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. <i>Gastroenterología Y Hepatología</i> , 2016 , 39, 255-60	0.9	3
190	European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian Centers. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2016 , 5, 9	0.3	0
189	Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 583-98	4.5	1
188	Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 400-26	6.1	39
187	Monitoring thiopurine metabolites in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2016 , 7, 301-307	2.6	17
186	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016 , 39, 697-721	0.1	4
185	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016 , 122, 33-41	6	9

184	In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. <i>Evidence-Based Medicine</i> , 2016 , 21, 144		1
183	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterology Y Hepatologia (English Edition)</i> , 2016 , 39, 677-686	0.1	1
182	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1020	6.1	
181	Helicobacter pylori-related diseases. <i>Gastroenterologia Y Hepatologia</i> , 2016 , 39 Suppl 1, 36-46	0.9	3
180	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterologia Y Hepatologia</i> , 2016 , 39, 677-686	0.9	6
179	The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. <i>Gastroenterology</i> , 2016 , 151, 51-69.e14	13.3	443
178	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. <i>Gastroenterologia Y Hepatologia</i> , 2016 , 39, 697-721	0.9	80
177	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016 , 14, 133	11.4	67
176	Letter: Helicobacter pylori infection and eosinophilic oesophagitis - causal or casual inverse association?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1244	6.1	2
175	Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 458-64	4	36
174	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 379-86	2.4	18
173	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 613-23	6.1	184
172	European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 211-22	1.5	278
171	Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2447-55	5.1	82
170	Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 768-75	6.1	72
169	Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49, 34-40	3	46
168	Response to: accuracy of GastroPanel test in detection of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 105-6	2.2	0
167	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 1063-70	1.5	36

166	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3075-84	4	21
165	The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. <i>United European Gastroenterology Journal</i> , 2015 , 3, 539-50	5.3	54
164	Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 494-5	6.1	1
163	Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1302-3	6.1	
162	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 847-58.e4; quiz e48-50	6.9	246
161	Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second-line regimen in the presence of levofloxacin resistance--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1221-2	6.1	1
160	Letter: clarithromycin dose for H.pylori therapy remains unresolved. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 631-2	6.1	
159	Letter: sitafloxacin for H.pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 942-3	6.1	1
158	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 940-1	6.1	1
157	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 391-405	6.1	68
156	Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates. <i>Frontiers in Immunology</i> , 2015 , 6, 512	8.4	101
155	Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. <i>Mediators of Inflammation</i> , 2015 , 2015, 318207	4.3	14
154	Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2260-2	5.6	10
153	Rectal hypersensitivity in patients with quiescent ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 592	1.5	4
152	Treatment of Helicobacter pylori Infection 2015. <i>Helicobacter</i> , 2015 , 20 Suppl 1, 54-61	4.9	26
151	Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study. <i>Gastroenterology</i> , 2015 , 148, 794-805	13.3	39
150	Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015 , 47, 108-13	3.3	18
149	Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPRICON study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 581-9	6.1	54

148	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11273-81	5.6	35
147	Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 383-9	4	37
146	Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. <i>Gut</i> , 2014 , 63, 244-9	19.2	97
145	Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. <i>Human Immunology</i> , 2014 , 75, 71-5	2.3	33
144	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1529-38	1.5	28
143	How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1749-62	4.1	10
142	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014 , 23, 6927-34	5.6	31
141	Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 183-90	1.5	24
140	Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 654-61	1.5	18
139	Optimum second-line regimens for Helicobacter pylori eradication. <i>The Cochrane Library</i> , 2014 ,	5.2	1
138	Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10338-47	5.6	48
137	Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 645-59	6.1	169
136	Letter: acute severe ulcerative colitis - should all patients be treated equally?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 113	6.1	1
135	Systematic review with meta-analysis: inflammatory bowel disease in the elderly. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 459-77	6.1	105
134	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 941-8	2.2	43
133	Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 240-51	1.5	65
132	Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1287-93	1.5	22
131	Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. <i>Current Drug Metabolism</i> , 2014 , 15, 875-81	3.5	2

130	Optimized nonbismuth quadruple therapies cure most patients with <i>Helicobacter pylori</i> infection in populations with high rates of antibiotic resistance. <i>Gastroenterology</i> , 2013 , 145, 121-128.e1	13.3	152
129	Health care costs of complex perianal fistula in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 3400-6	4	24
128	Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. <i>Drugs</i> , 2013 , 73, 1761-70	12.1	31
127	Treatment of <i>Helicobacter pylori</i> infection 2013. <i>Helicobacter</i> , 2013 , 18 Suppl 1, 58-65	4.9	41
126	<i>Helicobacter pylori</i> inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2013 , 68, 284-90	6.8	11
125	Letter: mucosal healing in ulcerative colitis--higher relevance than in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 207	6.1	1
124	Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 992	6.1	1
123	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 717-22	1.5	61
122	Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. <i>Gastroenterología Y Hepatología</i> , 2013 , 36, 104-14	0.9	25
121	Reply to Dr. Katsanos et al.'s letter. <i>Journal of Crohns and Colitis</i> , 2013 , 7, e23-4	1.5	
120	Safety of thiopurines and anti-TNF- α drugs during pregnancy in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, 433-40	0.7	157
119	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter pylori</i> eradication). <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 843-61	4	62
118	Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. <i>International Journal of Cancer</i> , 2013 , 133, 1023-32	7.5	65
117	Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1426-38	0.7	88
116	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 652-6	2.4	25
115	Letter: infliximab in severe ulcerative colitis - is it useful for all patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1413	6.1	1
114	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 752-60	6.1	58
113	<i>Helicobacter Pylori</i> "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. <i>Clinical and Translational Gastroenterology</i> , 2013 , 4, e32	4.2	35

112	Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 554-8	4.5	30
111	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013 , CD008337.2	3.2	80
110	Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1404-10	4.5	190
109	Impact of current smoking on the clinical course of microscopic colitis. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1470-6	4.5	45
108	Second-line therapy with levofloxacin after failure of treatment to eradicate <i>Helicobacter pylori</i> infection: time trends in a Spanish Multicenter Study of 1000 patients. <i>Journal of Clinical Gastroenterology</i> , 2013 , 47, 130-5	3	51
107	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 411-7	4.5	61
106	Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1379-85	6.1	62
105	Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1484-5; author reply 1486	6.1	18
104	High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high <i>Helicobacter pylori</i> eradication rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 190-6	6.1	24
103	Commentary: comparators in <i>H. pylori</i> eradication--stating the ethics of statins. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 400-1	6.1	3
102	Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 414-25	6.1	111
101	Treatment of <i>Helicobacter pylori</i> infection 2012. <i>Helicobacter</i> , 2012 , 17 Suppl 1, 36-42	4.9	27
100	Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 812-812	6.1	
99	Letter: are lymphocytic colitis and collagenous colitis really the same disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 606	6.1	8
98	Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible <i>Helicobacter pylori</i> and versus sequential therapy for clarithromycin-resistant strains. <i>Helicobacter</i> , 2012 , 17, 269-76	4.9	64
97	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1909-15	4.0	394
96	Long-term follow-up of 1,000 patients cured of <i>Helicobacter pylori</i> infection following an episode of peptic ulcer bleeding. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1197-204	0.7	51
95	Systematic review: antibodies and anti-TNF levels in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 971-86	6.1	72

94	Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1460-6	0.7	98
93	Intensification of infliximab therapy in Crohn's disease: efficacy and safety. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 62-7	1.5	32
92	Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012 , 61, 646-64	19.2	1615
91	Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. <i>Clinical and Experimental Gastroenterology</i> , 2012 , 5, 23-34	3.1	98
90	Long-term durability of response to adalimumab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 685-90	4.5	43
89	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2026-33	4.5	100
88	Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 275-83	6.1	83
87	Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 209-21	6.1	132
86	Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 941-7	6.1	50
85	Rescue Therapy for Helicobacter pylori Infection 2012. <i>Gastroenterology Research and Practice</i> , 2012 , 2012, 974594	2	31
84	Effectiveness of infliximab after adalimumab failure in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5219-24	5.6	22
83	Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. <i>Gastroenterología Y Hepatología</i> , 2011 , 34, 443-8	0.9	22
82	Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 113-8	3	97
81	Is culture necessary before first-line treatment for Helicobacter pylori infection?. <i>Internal Medicine</i> , 2011 , 50, 2717; author reply 2719-20	1.1	15
80	Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 340-8	6.1	76
79	Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 604-17	6.1	116
78	Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1047-62	6.1	39
77	Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1255-68	6.1	88

76	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 619-33	6.1	87
75	Has <i>H. pylori</i> prevalence in bleeding peptic ulcer been underestimated? A meta-regression. <i>American Journal of Gastroenterology</i> , 2011 , 106, 398-405	0.7	60
74	Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. <i>Current Pharmaceutical Biotechnology</i> , 2011 , 12, 765-73	2.6	32
73	Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 144-52	1.5	119
72	Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 567-74	1.5	27
71	<i>Helicobacter pylori</i> first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. <i>Digestive and Liver Disease</i> , 2010 , 42, 287-90	3.3	43
70	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication 2010 ,		2
69	Sequential therapy for <i>Helicobacter pylori</i> eradication: a critical review. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 313-25	3	159
68	Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 881-95	4.5	100
67	Anemia and inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2009 , 15, 4659-65	5.6	127
66	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: a European observational study. <i>European Journal of General Practice</i> , 2009 , 15, 154-60	2.8	7
65	Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1485-91	4.5	88
64	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1190-8	4.5	222
63	Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 126-37	6.1	152
62	Review article: <i>Helicobacter pylori</i> -negative duodenal ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 791-815	6.1	83
61	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009 , 41, 56-66	3.3	166
60	Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. <i>Health and Quality of Life Outcomes</i> , 2009 , 7, 90	3	47
59	Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. <i>American Journal of Gastroenterology</i> , 2009 , 104, 760-7	0.7	486

58	Management of gastro-oesophageal reflux disease in primary care: a European observational study. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2777-84	2.5	11
57	Pyrrolidinium-type fullerene derivative-induced apoptosis by the generation of reactive oxygen species in HL-60 cells. <i>European Journal of General Practice</i> , 2009 , 43, 1240-7	2.8	10
56	Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 868-77	6.1	77
55	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. <i>Gastroenterología Y Hepatología</i> , 2008 , 31, 421-6	0.9	21
54	Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1299-307	0.7	151
53	Second-line rescue therapy with levofloxacin after <i>H. pylori</i> treatment failure: a Spanish multicenter study of 300 patients. <i>American Journal of Gastroenterology</i> , 2008 , 103, 71-6	0.7	65
52	Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1783-800	0.7	180
51	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 346-54	6.1	64
50	"Rescue" regimens after <i>Helicobacter pylori</i> treatment failure. <i>World Journal of Gastroenterology</i> , 2008 , 14, 5385-402	5.6	82
49	5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 629-38	4.5	144
48	Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 1106-14	4.5	88
47	First-line triple therapy with levofloxacin for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 495-500	6.1	44
46	Eradication of <i>Helicobacter pylori</i> for the prevention of peptic ulcer rebleeding. <i>Helicobacter</i> , 2007 , 12, 279-86	4.9	21
45	¹³ C-urea breath test during hospitalization for the diagnosis of <i>Helicobacter pylori</i> infection in peptic ulcer bleeding. <i>Helicobacter</i> , 2007 , 12, 231-7	4.9	21
44	Evolution of <i>Helicobacter pylori</i> therapy from a meta-analytical perspective. <i>Helicobacter</i> , 2007 , 12 Suppl 2, 50-8	4.9	60
43	Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 1262-9	4	67
42	Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1518-27	0.7	153
41	Accuracy of <i>Helicobacter pylori</i> diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2006 , 101, 848-63	0.7	154

40	Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1921-30	0.7	183
39	Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. <i>American Journal of Gastroenterology</i> , 2006 , 101, 243-7	0.7	83
38	Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2769-76	0.7	88
37	Risk assessment and outpatient management in bleeding peptic ulcer. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 129-34	3	12
36	Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 35-44	6.1	248
35	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1469-74	6.1	62
34	Gastric MALT lymphoma: clinical characteristics and prevalence of H. pylori infection in a series of 37 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006 , 98, 655-65	0.9	9
33	Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. <i>Hepato-Gastroenterology</i> , 2006 , 53, 399-404		7
32	Evaluation of 3 different tests for the detection of stool antigens to confirm Helicobacter pylori eradication after treatment. A pilot study. <i>Gastroenterología Y Hepatología</i> , 2005 , 28, 615-8	0.9	13
31	Helicobacter pylori "rescue" therapy after failure of two eradication treatments. <i>Helicobacter</i> , 2005 , 10, 363-72	4.9	78
30	Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 1411-8	6.1	159
29	7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 1249-53	6.1	9
28	Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 1041-6	6.1	44
27	Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1935-40	7	30
26	Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 617-29	6.1	100
25	Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pylori infection in patients with upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 923-9	6.1	32
24	Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 1001-17	6.1	237
23	The TETRA study: a prospective evaluation of Helicobacter pylori 'test-and-treat' strategy on 736 patients in clinical practice. <i>Helicobacter</i> , 2004 , 9, 28-38	4.9	30

22	Empirical <i>Helicobacter pylori</i> "rescue" therapy after failure of two eradication treatments. <i>Digestive and Liver Disease</i> , 2004 , 36, 7-12	3.3	19
21	Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 689-92	2.2	30
20	The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 135-8	2.2	21
19	Pantoprazole based therapies in <i>Helicobacter pylori</i> eradication: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 89-99	2.2	20
18	H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. <i>Cochrane Database of Systematic Reviews</i> , 2003 , CD004062		5
17	'Rescue' therapy with rifabutin after multiple <i>Helicobacter pylori</i> treatment failures. <i>Helicobacter</i> , 2003 , 8, 90-4	4.9	80
16	Review article: is there an optimal therapeutic regimen for antimicrobial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 17-27	6.1	16
15	Systematic review: Rabeprazole-based therapies in <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 751-64	6.1	24
14	Triple vs quadruple therapy for treating <i>Helicobacter pylori</i> infection: an updated meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 18, 543-4	6.1	31
13	Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2003 , 39, 620-7	13.4	119
12	Attitude facing a patient suffering from <i>Helicobacter pylori</i> infection resistant to a triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2003 , 95, 220-8, 210-19	0.9	0
11	Single vs. double dose of a proton pump inhibitor in triple therapy for <i>Helicobacter pylori</i> eradication: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 1149-56	6.1	84
10	Review article: <i>Helicobacter pylori</i> "rescue" regimen when proton pump inhibitor-based triple therapies fail. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 1047-57	6.1	160
9	Role of partner's infection in reinfection after <i>Helicobacter pylori</i> eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 865-71	2.2	33
8	The stool antigen test for detection of <i>Helicobacter pylori</i> after eradication therapy. <i>Annals of Internal Medicine</i> , 2002 , 136, 280-7	8	88
7	A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 603-9	6.1	168
6	Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 1319-28	6.1	129
5	Seven-day 'rescue' therapy after <i>Helicobacter pylori</i> treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. <i>Alimentary Pharmacology and Therapeutics</i> , 1999 , 13, 1311-6	6.1	64

4	Helicobacter pylori test-and-treat' strategy for dyspeptic patients. <i>Scandinavian Journal of Gastroenterology</i> , 1999 , 34, 644-52	2.4	14
3	Prevalence of Helicobacter pylori infection in medical professionals in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 239-42	2.2	17
2	Helicobacter pylori and gastroesophageal reflux disease: friends or foes?. <i>Hepato-Gastroenterology</i> , 1999 , 46, 1023-9		14
1	Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. <i>Scandinavian Journal of Gastroenterology</i> , 1998 , 33, 1144-51	2.4	40